Comparing Short and Long Dual Antiplatelet Therapy After Carotid Artery Stenting in Patients with High Bleeding Risk

What this Trial Is About

Researchers are studying the best length of dual antiplatelet therapy DAPT after carotid artery stenting CAS in patients who have a high risk of bleeding. This trial, called CHET, is a multicenter, randomized, open-label study conducted in stroke centers across the Republic of Korea. It aims to compare shorter versus longer DAPT durations to see if a shorter treatment reduces bleeding while maintaining similar protection against stroke and heart problems. All participants first receive aspirin and clopidogrel for 30 days after CAS. Those without major clinical events at 30 days are then randomly assigned to either continue dual therapy for 11 more months or switch to a single antiplatelet medication for 11 months. The study carefully monitors bleeding events and cardiovascular outcomes during this treatment period. Participants have scheduled follow-up visits at 5 and 11 months after randomization, with yearly check-ins afterward by phone or in person until the study ends. Researchers collect clinical data to measure bleeding and combined cardiovascular events. The total participation time spans from the initial stenting procedure through up to several years of follow-up to track long-term health outcomes.

Highest Efficacy of Dual Antiplatelet Therapy After Carotid Artery Stenting in High Bleeding Risk Patients